Stereotaxis, Inc. (STXS)

Stereotaxis's stock price has experienced significant fluctuations over the last six months. In November 2025, the FDA approved the GenesisX system, Stereotaxis reported Q3 financial results showing a loss, Roth Capital reiterated a "Buy" recommendation, and the company participated in the Piper Sandler Healthcare Conference. In July 2025, the magnetic mapping catheter received FDA approval, and Stereotaxis acquired Access Point Technologies EP. In August 2025, the company received a CE mark in Europe for GenesisX. In May 2025, Stereotaxis received CE mark recertification under the EU's new Medical Device Regulation (MDR) regulatory framework. In March 2025, Stereotaxis filed for FDA approval of magnetically navigated catheters. In January 2025, Stereotaxis announced the first order for GenesisX and European CE mark approval of its robotically-navigated magnetic ablation catheter. New product approvals and a transition to higher-margin recurring revenue streams are seen as positive, but volatile systems sales and pending regulatory approvals have tempered overall growth.

Specific data on the demand seasonality for Stereotaxis's products and services is not readily available. The company generates revenue from the sale of robotic systems and recurring revenue from disposable devices, accessories, and service contracts. Stereotaxis is actively transitioning towards higher-margin recurring revenue streams, which inherently tend to be less seasonal and more predictable than one-time system sales. While system sales can be volatile, the increasing focus on recurring revenue from disposables and services suggests a move towards a more stable demand profile over time.

Stereotaxis, Inc. is a medical technology company specializing in robotic systems for minimally invasive endovascular procedures, focusing on improving the treatment of cardiac arrhythmias and coronary artery disease through its Robotic Magnetic Navigation (RMN) technology. The company's major products include Robotic Magnetic Navigation Systems like the Niobe and Genesis RMN Systems, imaging and mapping solutions such as EMAGIN Map-iT, disposable interventional devices and accessories like the MAGiC catheter, information systems like the Odyssey Solution, X-ray Systems like the Stereotaxis Imaging Model S, and the Vdrive System.

Stereotaxis markets its products globally through a direct sales force, distributors, and sales agents in the United States, Europe, and other parts of the world. As of 2017, its RMN system had been used in over 100,000 procedures worldwide. In January 2022, the Fuwai Central China Cardiovascular Hospital became the first in central China to establish a robotic electrophysiology program using Stereotaxis products.

Stereotaxis's brand reputation appears to be generally positive, driven by significant product advancements and regulatory successes. The company has received FDA approval for its GenesisX system and a magnetic mapping catheter, and CE mark approvals in Europe for GenesisX and a robotically-navigated magnetic ablation catheter. Analyst ratings also reflect a positive outlook, with a consensus "Buy" rating and a predicted upside for the stock. The expansion of robotic electrophysiology programs in international markets, such as central China, further enhances its global reputation.

Stereotaxis is owned by a mix of institutional shareholders and insiders. Institutional shareholders hold 44.81% of the company, while Stereotaxis insiders hold 116.25%. Nathan Fischel is the largest individual shareholder, owning 60.78% of the company. Other major owners include Dafna Capital Management LLC, Joe E. Kiani, Paul J. Isaac, Lagoda Investment Management LP, Blackrock Inc., Fred A. Middleton, Vanguard Group Inc., and Arbiter Partners Capital Management LLC.